CoChat

Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes

Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., Home, P. D. · 2006 · Diabetic Medicine
Cited by 118

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Aims To compare blood glucose control using insulin glargine + insulin lispro with that on NPH insulin + unmodified human insulin in adults with Type 1 diabetes managed with a multiple injection regimen. Methods In this 32‐week, five‐centre, two‐way cross‐over study, people with Type 1 diabetes (n = 56, baseline HbA 1c 8.0 ± 0.8%) were randomized to evening insulin glargine + mealtime insulin lispro or to NPH insulin (once‐ or twice‐daily) + mealtime unmodified human insulin. Each 16‐week period concluded with a 24‐h inpatient plasma glucose profile. Results HbA 1c was lower with glargine + lispro than with NPH + human insulin [7.5 vs. 8.0%, difference −0.5 (95% CI −0.7, −0.3) %, P < 0.001]. This was confirmed by an 8% lower 24‐h plasma glucose area under the curve (AUC) (187 vs. 203 mmol l−1 h−1, P = 0.037), a 24% reduction in plasma glucose AUC > 7.0 mmol/l 1 (47 vs. 62 mmol l−1 h−1, P = 0.017) and a 15% lower post‐prandial plasma glucose AUC (75 vs. 88 mmol l−1 h−1, P = 0.002). There was no reduction in night‐time plasma glucose AUC or increase in plasma glucose area < 3.5 mmol/l. Monthly rate of nocturnal hypoglycaemia was reduced by 44% with glargine + lispro (0.66 vs. 1.18 episodes/month, P < 0.001). Conclusions Compared with NPH insulin + unmodified human insulin, the combination of insulin glargine with a rapid‐acting insulin analogue as multiple‐injection therapy for Type 1 diabetes improves overall glycaemic control as assessed by HbA 1c and 24‐h plasma glucose monitoring to a clinically significant degree, together with a reduction in nocturnal hypoglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1464-5491.2005.01781.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 118

Metadata

Authors
Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D.
Venue
Diabetic Medicine
Publisher
Wiley
Published
2006-02-16
Volume
23
Issue
3
Pages
285-292
ISSN
  • 0742-3071 (ISSN-L)
  • 1464-5491
OpenAlex
W1995427842
Cited by
118
References
7
FWCI
11.70
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes. https://app.cochat.ai/papers/10.1111/j.1464-5491.2005.01781.x
The paper
Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D. (2006). Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.2005.01781.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.